Is Ethosuximide registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 0 valid registrations of Ethosuximide.

Is Ethosuximide approved by the US FDA?

Drugs@FDA lists 10 application product lines for Ethosuximide, including ZARONTIN (Prescription); ZARONTIN (Prescription); ETHOSUXIMIDE (Prescription); ETHOSUXIMIDE (Prescription); ETHOSUXIMIDE (Prescription).

Is Ethosuximide on the WHO Model List of Essential Medicines?

Yes — 5.1.1. Antiseizure medicines (complementary list): Absence seizures, typical.

Are there safety signals or safety updates for Ethosuximide?

US FDA: 1 entry (latest 2021-10-28).

Active substance

Ethosuximide

SFDA 2
US FDA 10
Health Canada 4
US price lines 3
NHS prices 5
WHO EML 1
Safety 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
ZARONTIN CAP 250MG	250 mg	Capsule · Oral use	50 Blister	SAR 20.35	NCE · Prescription	PARK-DAVIS	Withdrawn by MAH · Not Marketed
ZARONTIN SYR 250MG-5ML	50 mg/ml	Syrup · Oral use	1 Bottle	SAR 35.20	NCE · Prescription	PARK-DAVIS	Withdrawn by MAH · Not Marketed

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
ZARONTIN	250MG	capsule · oral	PARKE DAVIS	Prescription	2 Nov 1960
ZARONTIN	250MG/5ML	syrup · oral	PARKE-DAVIS	Prescription	13 Feb 1974
ETHOSUXIMIDE	250MG/5ML	syrup · oral	PHARM ASSOC	Prescription	22 Nov 2000
ETHOSUXIMIDE	250MG	capsule · oral	BIONPHARMA	Prescription	28 Oct 2002
ETHOSUXIMIDE	250MG/5ML	syrup · oral	CHARTWELL RX	Prescription	22 Dec 2003
ETHOSUXIMIDE	250MG	capsule · oral	EPIC PHARMA LLC	Prescription	28 May 2008
ETHOSUXIMIDE	250MG	capsule · oral	ONESOURCE	Prescription	19 Feb 2019
ETHOSUXIMIDE	250MG	capsule · oral	PURACAP PHARM LLC	Prescription	16 Mar 2020
ETHOSUXIMIDE	250MG/5ML	syrup · oral	TEVA PHARMS	Discontinued	30 Jul 1993
ETHOSUXIMIDE	250MG	capsule · oral	HERITAGE PHARMS INC	Discontinued	25 Sep 2012

Canada Canada — marketed products (Health Canada)

Brand	DIN	Strength	Form · route	Company
MAR-ETHOSUXIMIDE	02545772	250 MG	CAPSULE · ORAL	MARCAN PHARMACEUTICALS INC
ODAN-ETHOSUXIMIDE	02547171	250 MG	CAPSULE · ORAL	ODAN LABORATORIESLTD
ZARONTIN	00022799	250 MG	CAPSULE · ORAL	SEARCHLIGHT PHARMA INC
ZARONTIN SYRUP	00023485	250 MG / 5 ML	SYRUP · ORAL	SEARCHLIGHT PHARMA INC

Prices — United States and England

Source	Product as listed	Price	Unit / pack	Date
US NADAC	ETHOSUXIMIDE 250 MG CAPSULE	$0.24349	per EA	23 Sep 2026
US NADAC	ETHOSUXIMIDE 250 MG/5 ML SOLN	$0.10045	per ML	23 Sep 2026
US NADAC	ZARONTIN 250 MG CAPSULE	$1.30857	per EA	1 Jan 2026
NHS Drug Tariff	Ethosuximide 250mg capsules	£21.91	56 capsule	1 Oct 2026
NHS Drug Tariff	Ethosuximide 250mg/5ml oral solution	£46.09	200 ml	1 Oct 2026
NHS Drug Tariff	Ethosuximide 250mg/5ml oral solution sugar free	£104.22	125 ml	1 Oct 2026
NHS Drug Tariff	Ethosuximide 250mg/5ml oral solution sugar free	£55.97	200 ml	1 Oct 2026
NHS Drug Tariff	Ethosuximide 250mg/5ml oral solution sugar free	£85.77	250 ml	1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

WHO WHO Model List of Essential Medicines (2025)

5.1.1. Antiseizure medicines · complementary
Absence seizures, typical
Oral > Liquid: 250 mg per 5 mL | Oral > Solid: 250 mg

Safety signals and safety-related labeling changes

US FDA 28 Oct 2021 ZARONTIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide

All safety entries for ethosuximide →

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.